m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00518)
Target Name Vimentin (vimentin)
Gene Name vimentin
Chromosomal Location 10p13
Family Intermediate filament family
Function
Vimentins are class-III intermediate filaments found in various non-epithelial cells, especially mesenchymal cells. Vimentin is attached to the nucleus, endoplasmic reticulum, and mitochondria, either laterally or terminally;Involved with LARP6 in the stabilization of type I collagen mRNAs for CO1A1 and CO1A2.
    Click to Show/Hide
Gene ID 7431
Uniprot ID
VIME_HUMAN
HGNC ID
HGNC:12692
Ensembl Gene ID
ENSG00000026025
KEGG ID
hsa:7431
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
vimentin can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Methyltransferase-like 3 (METTL3) [WRITER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3
Cell Line Caco-2 cell line Homo sapiens
Treatment: shMETTL3 Caco-2 cells
Control: shNTC Caco-2 cells
 GSE167075
Regulation
logFC: -9.97E-01
p-value: 8.40E-43
More Results Click to View More RNA-seq Results
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary METTL3 activated the luciferase activity of TOPflash (a reporter for beta-catenin/TCF signaling), and downregulation of METTL3 inhibited the expression of beta-catenin/TCF target genes Vimentin (vimentin) and N-cadherin, which are two regulators of epithelial-mesenchymal transition. METTL3 silencing decreased the m6A methylation and total mRNA levels of Tankyrase, a negative regulator of axin. METTL3 is a therapeutic target for NPC.
Target Regulation Up regulation
Responsed Disease Nasopharyngeal carcinoma ICD-11: 2B6B
 Disease Info 
Pathway Response Wnt signaling pathway hsa04310
Cell Process Epithelial-mesenchymal transition
In-vitro Model Neural progenitor cells (NPCs) (The progenitor cells of the CNS)
NP69 (A human immortalized nasopharyngeal epithelial)
HNE-2 Nasopharyngeal carcinoma Homo sapiens CVCL_FA07
HNE-1 Nasopharyngeal carcinoma Homo sapiens CVCL_0308
CNE-2 Nasopharyngeal carcinoma Homo sapiens CVCL_6889
CNE-1 Normal Homo sapiens CVCL_6888
In-vivo Model 1 × 105 HNE2 cells (with or without METTL3 knockdown) were labeled with luciferase gene and injected into the tail vein of the nude mice.
Nasopharyngeal carcinoma [ICD-11: 2B6B]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary METTL3 activated the luciferase activity of TOPflash (a reporter for beta-catenin/TCF signaling), and downregulation of METTL3 inhibited the expression of beta-catenin/TCF target genes Vimentin (vimentin) and N-cadherin, which are two regulators of epithelial-mesenchymal transition. METTL3 silencing decreased the m6A methylation and total mRNA levels of Tankyrase, a negative regulator of axin. METTL3 is a therapeutic target for NPC.
Responsed Disease Nasopharyngeal carcinoma [ICD-11: 2B6B]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Up regulation
Pathway Response Wnt signaling pathway hsa04310
Cell Process Epithelial-mesenchymal transition
In-vitro Model Neural progenitor cells (NPCs) (The progenitor cells of the CNS)
NP69 (A human immortalized nasopharyngeal epithelial)
HNE-2 Nasopharyngeal carcinoma Homo sapiens CVCL_FA07
HNE-1 Nasopharyngeal carcinoma Homo sapiens CVCL_0308
CNE-2 Nasopharyngeal carcinoma Homo sapiens CVCL_6889
CNE-1 Normal Homo sapiens CVCL_6888
In-vivo Model 1 × 105 HNE2 cells (with or without METTL3 knockdown) were labeled with luciferase gene and injected into the tail vein of the nude mice.
References
Ref 1 Upregulated METTL3 in nasopharyngeal carcinoma enhances the motility of cancer cells. Kaohsiung J Med Sci. 2020 Nov;36(11):895-903. doi: 10.1002/kjm2.12266. Epub 2020 Jul 15.